Development of effective pilot-scale technology for producing N,N-bis-met-histone H 1.3 used for lymphoma treatment

Much attention is presently devoted to the treatment of lymphoma using monoclonal antibodies. Unfortunately, preparations such as Rituximab (MabThera) are not produced in the Russian Federation and must be imported from abroad. It was shown that Hl-type histones with activities similar to that of Ri...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical chemistry journal Vol. 46; no. 4; p. 234
Main Authors: Gusarov, D.A, Sokolova, I.V, Gusarova, V.D, Evteeva, E.A, Vorobeva, T.V, Kosarev, S.A, Shibanova, E.D, Bairamashvili, D.I
Format: Journal Article
Language:English
Published: Springer 01-07-2012
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Much attention is presently devoted to the treatment of lymphoma using monoclonal antibodies. Unfortunately, preparations such as Rituximab (MabThera) are not produced in the Russian Federation and must be imported from abroad. It was shown that Hl-type histones with activities similar to that of Rituximab can be used for such therapy. We have developed an pilot-scale technology for the production of recombinant N,N-bis-met-histone H1.3. The activity and purity of the obtained preparation were demonstrated in several tests. The produced amount of active pharmaceutical ingredient was sufficient to start clinical trials in Russia. Key words: N,N-bis-met-histone H1.3, lymphoma, chromatography, technology.
ISSN:0091-150X